{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&sponsor=Canadian+Cancer+Trials+Group", "query": { "sponsor": "Canadian Cancer Trials Group", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 64, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=3&sponsor=Canadian+Cancer+Trials+Group&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=1&sponsor=Canadian+Cancer+Trials+Group&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T20:26:44.563Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00887146", "title": "Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "concomitant temozolomide (TMZ)", "type": "DRUG" }, { "name": "radiotherapy", "type": "RADIATION" }, { "name": "procarbazine", "type": "DRUG" }, { "name": "adjuvant temozolomide (TMZ)", "type": "DRUG" }, { "name": "CCNU", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 305, "start_date": "2009-09", "completion_date": "2029-10-31", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-10-08T20:26:44.563Z", "location_count": 271, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 185 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00887146" }, { "nct_id": "NCT02003222", "title": "Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Lymphoblastic Leukemia", "B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "30 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "30 Years to 70 Years" }, "enrollment_count": 488, "start_date": "2014-05-19", "completion_date": "2027-02-25", "has_results": true, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-08T20:26:44.563Z", "location_count": 531, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 328 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02003222" }, { "nct_id": "NCT02844816", "title": "Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Bladder Urothelial Carcinoma", "Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7", "Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7", "Stage I Bladder Urothelial Carcinoma AJCC v6 and v7" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 172, "start_date": "2017-03-13", "completion_date": "2024-06-26", "has_results": true, "last_update_posted_date": "2025-05-22", "last_synced_at": "2026-10-08T20:26:44.563Z", "location_count": 269, "location_summary": "Daphne, Alabama • Mobile, Alabama • Scottsdale, Arizona + 201 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02844816" }, { "nct_id": "NCT00036647", "title": "OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-small-cell Lung" ], "interventions": [ { "name": "Tarceva (erlotinib HCl, OSI-774 )", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OSI Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 731, "start_date": "2001-11-01", "completion_date": "2004-01-30", "has_results": false, "last_update_posted_date": "2018-01-10", "last_synced_at": "2026-10-08T20:26:44.563Z", "location_count": 2, "location_summary": "Chicago, Illinois • Seattle, Washington", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00036647" }, { "nct_id": "NCT06686771", "title": "Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "SBRT", "type": "RADIATION" }, { "name": "First or second-line standard of care therapy", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "OTHER" ], "sponsor": "Canadian Cancer Trials Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2025-12-16", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-10-08T20:26:44.563Z", "location_count": 71, "location_summary": "Phoenix, Arizona • Duarte, California • Irvine, California + 55 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Grand Junction", "state": "Colorado" }, { "city": "Newnan", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06686771" }, { "nct_id": "NCT04918186", "title": "Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "BA3011", "type": "DRUG" }, { "name": "BA3021", "type": "DRUG" }, { "name": "ENB003", "type": "DRUG" }, { "name": "Toripalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Canadian Cancer Trials Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 60, "start_date": "2022-05-03", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-08T20:26:44.563Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04918186" }, { "nct_id": "NCT03233191", "title": "Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Screening" ], "interventions": [ { "name": "Digital Mammography", "type": "PROCEDURE" }, { "name": "Digital Tomosynthesis Mammography", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": true, "eligibility": { "minimum_age": "45 Years", "maximum_age": "74 Years", "sex": "FEMALE", "summary": "45 Years to 74 Years · Female only" }, "enrollment_count": 108508, "start_date": "2017-09-28", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-08T20:26:44.563Z", "location_count": 133, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 107 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03233191" }, { "nct_id": "NCT03414970", "title": "Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ductal Breast Carcinoma", "Invasive Breast Carcinoma", "Lobular Breast Carcinoma", "Medullary Breast Carcinoma", "Stage II Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage IIIA Breast Cancer", "Tubular Breast Carcinoma" ], "interventions": [ { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Hypofractionated Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 898, "start_date": "2018-03-12", "completion_date": "2035-08", "has_results": true, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-10-08T20:26:44.563Z", "location_count": 846, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 544 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03414970" }, { "nct_id": "NCT03461952", "title": "Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Canadian Cancer Trials Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2019-03-11", "completion_date": "2022-02-09", "has_results": true, "last_update_posted_date": "2024-02-22", "last_synced_at": "2026-10-08T20:26:44.563Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03461952" }, { "nct_id": "NCT02773524", "title": "A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastro-Oesophageal Cancer" ], "interventions": [ { "name": "Regorafenib", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Australasian Gastro-Intestinal Trials Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2016-11", "completion_date": "2022-12", "has_results": false, "last_update_posted_date": "2022-01-13", "last_synced_at": "2026-10-08T20:26:44.563Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Urbana, Illinois + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Midlothian", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02773524" } ] }